Axtria Thought Leadership

Executive insights and perspectives on the Life Sciences industry
US Recession Pharma Analytics

White Paper

How Will The Next Great Recession Affect The US Pharma Industry?

The US will have another recession as certain as night follows day. The business cycle has not been outlawed nor made extinct, contrary to the overly optimistic views of macroecono ...

AstraZeneca’s Bold And Potentially Risky New Cancer Drug R&D Portfolio Strategy

Whitepaper

AstraZeneca’s Bold And Potentially Risky New Cancer Drug R&D Portfolio Strategy

This paper explores the challenges and opportunities this new strategy can have for AstraZeneca while providing other pharma companies that are contemplating a similar different R& ...

Incentive Compensation

White Paper

Perspectives On The Design And Effectiveness Of Pharma Sales Contests

This white paper covers an array of topics pertaining to the development, execution, and outcomes from sales contests to provide sales operations leaders practical guidance on key ...

Merger and Acquisitions

White Paper

Do Pharma Mergers And Acquisitions Improve R&D Productivity And Increase Shareholder Value?

Mergers & acquisitions (M&As) have long been used as a critical strategic instrument by pharmaceutical company executives to spur R&D innovation, sustain financial grow ...

Future of Pharma - Evolving Commercial Models

Report

Future Of Pharma: Evolving Commercial Models – Part 2

Learn what several senior pharma commercial operations leaders think of the potential implications of industry challenges on business operations, sales and marketing objectives and ...

Politics ‘Trumps’ Rational Policy Rule Change On Ending Rebates To PBMs For The Medicare Program

White Paper

Politics ‘Trumps’ Rational Policy Rule Change On Ending Rebates To PBMs For The Medicare Program

This paper explores the reason behind this about-face, potential policy alternatives President Trump may pursue to reduce drug prices and their adverse consequences, and what shoul ...

Traditional Call Planning

White Paper

Has Traditional Call Planning Passed Its Prime?

This paper explores simple and more complex additions and solutions to a myriad of issues facing future changes to call planning. A central theme in all the proposed solutions is t ...

Future of Pharma - Evolving Commercial Models

Report

Future Of Pharma: Evolving Commercial Models – Part 1

The pharmaceutical industry is in a state of flux with the increasing influence of payers, pressure from the government with restricted healthcare budgets, and the rise of multi-ch ...

PBMs Pharma Benefit Manager

White Paper

Proposed Rule To End Rebates To PBMs For Medicare And Medicaid Programs

This white paper looks at how rebates to PBMs relate to drug prices from two perspectives: how they are supposed to work versus what actually happens. ...